20
Participants
Start Date
October 17, 2016
Primary Completion Date
January 23, 2019
Study Completion Date
January 23, 2019
Radiation Therapy (RT)
2 Gy fractions once a day, 5 days per week, for a total of 60 Gy in 30 fractions.
Cisplatin
Concurrently with radiation therapy, 50 mg/m2, IV, on days 1, 8, 29, and 36, to begin with day 1 of radiation therapy.
Etoposide
Concurrently with radiation, 40 mg/m2, IV, on days 1-5 and 29-33, to begin with day 1 of radiation therapy.
Nivolumab
Beginning 4-12 weeks after chemoradiation, 240 mg, IV, every 2 weeks for 16 weeks, then 480 mg, IV, for 36 weeks.
Placebo
Beginning 4-12 weeks after chemoradiation, 240 mg, IV, every 2 weeks for 16 weeks, then 480 mg, IV, for 36 weeks.
Memorial Sloan Kettering Cancer Center, New York
University of Rochester, Rochester
Reading Hospital/McGlinn Cancer Institute, West Reading
Mercy Medical Cancer Center, Baltimore
Inova Fairfax Hospital, Falls Church
Nancy N. & J.C. Lewis Cancer & Research Pavilion at St. Joseph's/Candler Hospital, Savannah
University of Florida, Gainesville
Mount Sinai Cancer Research Center, Miami Beach
University of Kentucky, Lexington
Metro Health Medical Center, Cleveland
Henry Ford Health System, Detroit
University of Wisconsin Hospital and Clinics, Madison
University of Texas Southwestern Medical Center, Dallas
UC San Diego Moores Cancer Center, La Jolla
Stanford University, Stanford
Virginia Mason, Seattle
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
RTOG Foundation, Inc.
OTHER